xml in pharma – weve done spl, whats next? scientific sarah powell executive director, regulatory...
TRANSCRIPT
![Page 1: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/1.jpg)
XML in Pharma – We’ve Done SPL, What’s Next?SCIENTIFIC
SARAH POWELL
EXECUTIVE DIRECTOR, REGULATORY STRATEGIES
PHILADELPHIA, PA. FEBRUARY 2006
![Page 2: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/2.jpg)
Agenda
• What is XML?
• Review of XML-related regulatory initiatives
• Other potential uses of XML
• Path forward for your organization
![Page 3: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/3.jpg)
What is XML?
• Extensible Markup Language– Developed to aid creation, sharing and publishing of information
• A global standard for adding structure to content – Open standard of the W3C (World Wide Web Consortium)
– Extensible: User-defined and industry standard vocabularies
– Markup: Defines a hierarchical structure via embedded instructions Meaning (semantics) vs. Presentation (format)
• XML describes what content is; HTML describes what it looks like
– Language: A “meta-language” - syntax & rules on which other languages can be based
![Page 4: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/4.jpg)
Data ModelStructure and Rules
ContentNarrative and Data
+
Style SheetsOutput presentations
+
=
Desired Output
XML is a means of adding structure and intelligence to typically unstructured information
![Page 5: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/5.jpg)
Word ProcessingXML Content
Centered, 20 pt, bold, TNR
Centered, 15 pt, bold, TNR
Title, Centered 15 pt Arial, Blue
Body Text, 12 pt, TNR, Left Justified
Proprietary Name
Nonproprietary NameDosage Form
Section Title
Paragraph
Reference to Graphic fileFigure
Word Processing vs. Structured Authoring
ANTIBIOTICX(cephakillitall)
TABLETSANTIBIOTICX
(cephakillitall)ORAL SUSPENSION
DESCRIPTION
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ANTIBIOTICX Tablets and ANTIBIOTICX Oral Suspension and other antibacterial drugs, ANTIBIOTICX Tablets and ANTIBIOTICX Oral Suspension should only be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
ANTIBIOTICX® (cephakillitall) Tablets and ANTIBIOTICX® (cephakillitall) Oral Suspension are synthetic broad spectrum antimicrobial agents for oral administration…and its chemical structure is:
![Page 6: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/6.jpg)
Agenda
• What is XML?
• Review of XML-related regulatory initiatives
• Other potential uses of XML
• Path forward for your organization
![Page 7: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/7.jpg)
XML Touch Points in Pharma
Nonclinical Research
Clinical Research
Manufacturing & Quality
Electronic SubmissionsSafety & Surveillance
![Page 8: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/8.jpg)
• SEND– Standard for Exchange of Nonclinical Data
– Defines domains and variables for submitting data generated from animal toxicity studies
• Initiative began in July 2002• SEND model v.1 released Aug 2003• Current version is 2.3
– Domain categories:• Interventions• Findings • Special Purpose
– A list of variables are used to define specific domains:
• Body Weights, Clinical Pathology, Microscopic Findings, etc.
– References Study Data Tabulation Model (SDTM)
– XML format will replace SAS Transport files
Nonclinical Research
XML Touch Points in Pharma
![Page 9: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/9.jpg)
• Clinical Research / e-Clinical Trials – ODM (Operational Data Model)
– LAB (Laboratory Standards Model)
– SDTM (Submission Data Standards)
– ADaM (Analysis Dataset Model)
– CRT-DDS (Case Report Tabulation)
• Related Healthcare Initiatives (Clinical Care) – CDA (Clinical Document Architecture)
Clinical Research
XML Touch Points in Pharma
![Page 10: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/10.jpg)
– Structured Protocol• Protocol elements based on ICH and
Agency Standards
• Organization based on HL7 Reference Information Model (RIM 3)
• Transport in XML
• Viewing tools and repository available to reviewers
– Study Reports – Study Tagging Files• Based on ICH E3 and eCTD Guidance
• Information related to study report
Clinical Research
XML Touch Points in Pharma
![Page 11: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/11.jpg)
• Stability– Standard for submission of
stability data to FDA– Implementation Guide
availableManufacturing &
Quality
XML Touch Points in Pharma
![Page 12: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/12.jpg)
• eCTD
• SPL
• PIMElectronic Submissions
XML Touch Points in Pharma
![Page 13: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/13.jpg)
• Adverse Event Reports– ICSR
– EVMPDSafety & Surveillance
XML Touch Points in Pharma
![Page 14: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/14.jpg)
Agenda
• What is XML?
• Review of XML-related regulatory initiatives
• Other potential uses of XML
• Path forward for your organization
![Page 15: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/15.jpg)
XML Authoring Possibilities
• eCTD• Labeling (SPL/PIM)• AERs• CMC or Quality Info
• Study Protocols & Reports• Medical Inquiries• Promotional Materials
• Correspondence/Q&A• Presentations• Meeting Minutes
![Page 16: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/16.jpg)
Standard Driven
• eCTD• Labeling (SPL/PIM)• AERs• CMC or Quality Info
• Study Protocols & Reports• Medical Inquiries• Promotional Materials
• Correspondence/Q&A• Presentations• Meeting Minutes
![Page 17: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/17.jpg)
Let’s Explore
• eCTD• Labeling (SPL/PIM)• AERs• CMC or Quality Info
• Study Protocols &Reports• Medical Inquiries• Promotional Materials
• Correspondence/Q&A• Presentations• Meeting Minutes
![Page 18: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/18.jpg)
![Page 19: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/19.jpg)
Human Readable
Machine Readable
Module 3 – 3.2.S.2.2
![Page 20: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/20.jpg)
US Submission
![Page 21: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/21.jpg)
EU Submission
Step Details excluded
![Page 22: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/22.jpg)
Agenda
• What is XML?
• Review of XML-related regulatory initiatives
• Other potential uses of XML
• Path forward for your organization
![Page 23: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/23.jpg)
Organizational Focus
• Strategic Thinking– Implementation provides an opportunity to gain efficiencies
while improving quality
– Approach as business strategy• Focus on solving business problems not just compliance
• Identify opportunities and prioritize
– Choose technologies that have scalability and flexibility
– Select “Quick Wins” to build internal confidence and solution credibility
SPL is best thing to raise awareness of XML
![Page 24: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/24.jpg)
Strategic Implementation
• Document enterprise view of strategic approach to XML implementation:– Document Analysis:
• Which documents share information?• How much reuse does the content offer?• Can information be structured and delivered via publishing?
– Common business processes• How is content utilized by various stakeholders?• What are the lifecycle requirements of the content?
– Publishing• Who requires access to the final documentation?• What publishing formats are needed and when?• Are separate controls (lifecycle, archiving, etc.) needed?
![Page 25: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/25.jpg)
• Identify tools that are scalable and flexible to support the enterprise– Authoring and publishing
• Implementation based on company priorities– Which document types to tackle first?
Strategic Implementation cont.
![Page 26: XML in Pharma – Weve Done SPL, Whats Next? SCIENTIFIC SARAH POWELL EXECUTIVE DIRECTOR, REGULATORY STRATEGIES PHILADELPHIA, PA. FEBRUARY 2006](https://reader036.vdocument.in/reader036/viewer/2022062511/55143358550346dd488b60ca/html5/thumbnails/26.jpg)
Conclusions
• SPL and PIM are the first of many XML initiatives affecting life sciences organizations.
• Plan for enterprise adoption– Establish business rules around the creation, use, reuse, and
lifecycle of content
– Embrace the technology and the opportunity to gain efficiencies